Ernest J. Mui

Garscube Estate
Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

The Microbial Trojan Horse and Antimicrobial Resistance: Acanthamoeba as an Environmental Reservoir for Multidrug Resistant Bacteria.

The Microbial Trojan Horse and Antimicrobial Resistance: Acanthamoeba as an Environmental Reservoir for Multidrug Resistant Bacteria.

Journal: Environmental microbiology

Published: June 04, 2025

Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors.

Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors.

Journal: Current pediatrics reports

Published: September 25, 2023

Building Programs to Eradicate Toxoplasmosis Part II: Education.

Building Programs to Eradicate Toxoplasmosis Part II: Education.

Journal: Current pediatrics reports

Published: March 27, 2023

MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer.

MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer.

Journal: British journal of cancer

Published: August 19, 2022

Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer.

Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer.

Journal: BJU international

Published: July 18, 2022

Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview.

Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview.

Journal: Current pediatrics reports

Published: April 29, 2022

Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances "Take a Village".

Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances "Take a Village".

Journal: Current pediatrics reports

Published: April 29, 2022

THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer.

THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer.

Journal: EMBO molecular medicine

Published: June 23, 2021

Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.

Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.

Journal: Cancer research

Published: May 04, 2021

Discontinuation Patterns and Cost Avoidance of a Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus Nasal Polymerase Chain Reaction Testing Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia.

Discontinuation Patterns and Cost Avoidance of a Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus Nasal Polymerase Chain Reaction Testing Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia.

Journal: Open forum infectious diseases

Published: December 31, 2020

18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy.

18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy.

Journal: EJNMMI research

Published: June 18, 2020

PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer.

PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer.

Journal: Oncogene

Published: October 01, 2019

Showing 1-12 of 33

Last Updated: 09/26/2026